Invention Grant
- Patent Title: Sultam compound and application method thereof
-
Application No.: US16086721Application Date: 2017-03-22
-
Publication No.: US11111240B2Publication Date: 2021-09-07
- Inventor: Li Zhu , Xiaowei Duan , Liguang Dai , Zhao Yang , Yanqing Yang , Hui Zhang , Yuandong Hu , Yong Peng , Yongxin Han , Rui Zhao , Xin Tian , Shanchun Wang
- Applicant: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. , Lianyungang Runzhong Pharmaceutical Co., Ltd. , Centaurus Biopharma Co., Ltd.
- Applicant Address: CN Lianyungang; CN Lianyungang; CN Beijing
- Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus Biopharma Co., Ltd.
- Current Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.,Lianyungang Runzhong Pharmaceutical Co., Ltd.,Centaurus Biopharma Co., Ltd.
- Current Assignee Address: CN Lianyungang; CN Lianyungang; CN Beijing
- Agency: Nixon Peabody LLP
- Priority: CN201610165138.6 20160322
- International Application: PCT/CN2017/077612 WO 20170322
- International Announcement: WO2017/162157 WO 20170928
- Main IPC: C07D275/02
- IPC: C07D275/02 ; A61K31/425 ; A61K31/433 ; A61P35/00 ; C07D417/14 ; C07D417/04
Abstract:
Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.
Public/Granted literature
- US20210047314A1 Sultam Compound And Application Method Thereof Public/Granted day:2021-02-18
Information query
